<DOC>
	<DOCNO>NCT00252135</DOCNO>
	<brief_summary>This study multicenter , prospective , observational cohort study ~5000 Xolair-treated ~2500 non-Xolair-treated patient moderate severe persistent asthma positive skin test vitro reactivity aeroallergen .</brief_summary>
	<brief_title>A Study Xolair Evaluate Effectiveness Long-Term Safety Patients With Moderate Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Signed informed consent document ( case minor , consent must give child 's parent legally authorize representative ) â‰¥12 year age Physician diagnosis moderate severe persistent asthma Evidence history positive skin test vitro reactivity aeroallergen Willingness participate fully duration study ( 5 year ) For patient Xolairtreated cohort , receive least one dose Xolair therapy time enrollment Contraindication Xolair therapy ( e.g. , patient experience severe hypersensitivity reaction Xolair ) Acute asthma exacerbation within previous 2 week screen require follow : initiation systemic corticosteroid , increase dos systemic corticosteroid baseline , double inhaled corticosteroid , emergency room visit , hospitalization Acute flare significant systemic disease ( e.g. , infection , hematologic , renal , hepatic , cardiovascular disease , gastrointestinal disease ) , recent hospitalization disease within previous 2 month Use experimental drug within 30 day prior study screen Diagnosis cystic fibrosis For patient nonXolairtreated cohort , prior treatment Xolair</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Moderate severe asthma</keyword>
</DOC>